PMID- 27372908
OWN - NLM
STAT- MEDLINE
DCOM- 20170606
LR  - 20181113
IS  - 1432-0843 (Electronic)
IS  - 0344-5704 (Print)
IS  - 0344-5704 (Linking)
VI  - 78
IP  - 2
DP  - 2016 Aug
TI  - Association of concurrent acid-suppression therapy with survival outcomes and 
      adverse event incidence in oncology patients receiving erlotinib.
PG  - 427-32
LID - 10.1007/s00280-016-3087-6 [doi]
AB  - PURPOSE: Acid-suppression therapy is known to decrease the systemic exposure of 
      erlotinib. The erlotinib prescribing information recommends staggering dosing 
      with a histamine-2 receptor antagonist (H2RA) and avoiding concurrent use of a 
      proton pump inhibitor (PPI). This retrospective analysis evaluated the frequency 
      of concurrent acid-suppression therapy in oncology patients receiving erlotinib 
      and its association with outcomes. METHODS: All patients prescribed erlotinib 
      within UC San Diego Health System between February 26, 2011, and February 28, 
      2014, were assessed for eligibility, survival outcomes and adverse events. 
      RESULTS: Of the 76 patients in the analysis, 24 were prescribed both a PPI and an 
      H2RA with erlotinib therapy (31.6 %). The two patient groups, with (n = 24) and 
      without PPI/H2RA (n = 52), were similar in clinical characteristics and erlotinib 
      dose. One patient received an H2RA therapy alone and was excluded from the 
      analysis; no one received PPI therapy alone. Patients receiving erlotinib alone 
      had a longer median progression-free survival (PFS) compared to patients with 
      concurrent PPI/H2RA therapy (11.0 months vs. 5.3 months; P = 0.029). Overall 
      survival (OS) and incidence of rash and/or diarrhea did not correlate with use of 
      acid-suppression therapy. CONCLUSION: Nearly one-third of patients received 
      acid-suppression therapy. Patients treated with erlotinib and PPI/H2RA therapy 
      had shorter PFS, but similar OS and adverse event profile compared to those who 
      did not receive acid-suppression.
FAU - Lam, Lisa H
AU  - Lam LH
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 
      9500 Gilman Drive, MC 0657, San Diego, La Jolla, CA, 92093-0657, USA.
FAU - Capparelli, Edmund V
AU  - Capparelli EV
AD  - Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, 
      9500 Gilman Drive, MC 0657, San Diego, La Jolla, CA, 92093-0657, USA. 
      ecapparelli@ucsd.edu.
FAU - Kurzrock, Razelle
AU  - Kurzrock R
AD  - Center for Personalized Cancer Therapy and Division of Hematology and Oncology, 
      Moores Cancer Center, UC San Diego Health System, La Jolla, CA, USA.
LA  - eng
GR  - U54 HD071600/HD/NICHD NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
DEP - 20160702
PL  - Germany
TA  - Cancer Chemother Pharmacol
JT  - Cancer chemotherapy and pharmacology
JID - 7806519
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - DA87705X9K (Erlotinib Hydrochloride)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*administration & dosage/adverse effects
MH  - Disease-Free Survival
MH  - Drug Interactions
MH  - Erlotinib Hydrochloride/*administration & dosage/adverse effects
MH  - Female
MH  - Histamine H2 Antagonists/*administration & dosage
MH  - Humans
MH  - Incidence
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/*drug therapy
MH  - Proton Pump Inhibitors/*administration & dosage
MH  - Retrospective Studies
MH  - Survival Rate
PMC - PMC4967016
MID - NIHMS800246
OTO - NOTNLM
OT  - Erlotinib
OT  - Histamine-2 receptor antagonist
OT  - Oncology
OT  - Proton pump inhibitor
OT  - Survival
EDAT- 2016/07/04 06:00
MHDA- 2017/06/07 06:00
PMCR- 2017/08/01
CRDT- 2016/07/04 06:00
PHST- 2016/05/15 00:00 [received]
PHST- 2016/06/09 00:00 [accepted]
PHST- 2016/07/04 06:00 [entrez]
PHST- 2016/07/04 06:00 [pubmed]
PHST- 2017/06/07 06:00 [medline]
PHST- 2017/08/01 00:00 [pmc-release]
AID - 10.1007/s00280-016-3087-6 [pii]
AID - 10.1007/s00280-016-3087-6 [doi]
PST - ppublish
SO  - Cancer Chemother Pharmacol. 2016 Aug;78(2):427-32. doi: 
      10.1007/s00280-016-3087-6. Epub 2016 Jul 2.